2024/07/16 17:35:10 | |
---|---|
Price | |
24.24 EUR | |
Difference | -0.90% (-0.22) |
ISIN | BE0003818359 |
Symbol | GLPG |
Exchange | Euronext Amsterdam |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 1,597 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | 23.80 EUR (21) |
Ask (Ask size) | 24.44 EUR (75) |
Open | 24.22 EUR |
High | 24.38 EUR |
Low | 23.80 EUR |
Close (prev. day) | 24.46 EUR |
VWAP | 24.131077 EUR |
Volume (pcs) | 46,079 |
Trading volume | 1,111,936.00 |
Number of trades | 656 |
Last size | 20 |
Related Futures | 24 |
Related Options | - |
Date | Headline | Download | |
2024/07/12 | Global Equity Ratings | ||
2024/06/21 | Global Equity Ratings | ||
2024/06/14 | Global Equity Ratings | ||
2024/05/29 | Global Equity Ratings | ||
2024/04/26 | Global Equity Ratings |
2024/07/16 17:35:10 | |
---|---|
Price | |
24.24 EUR | |
Difference | -0.90% (-0.22) |
ISIN | BE0003818359 |
Symbol | GLPG |
Exchange | Euronext Amsterdam |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 1,597 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | 23.80 EUR (21) |
Ask (Ask size) | 24.44 EUR (75) |
Open | 24.22 EUR |
High | 24.38 EUR |
Low | 23.80 EUR |
Close (prev. day) | 24.46 EUR |
VWAP | 24.131077 EUR |
Volume (pcs) | 46,079 |
Trading volume | 1,111,936.00 |
Number of trades | 656 |
Last size | 20 |
6m | 1Y | 3Y | |
Perf (%) | -31.99% | -34.73% | -51.81% |
Perf (abs.) | -11.40 | -12.90 | -26.06 |
Beta | 0.40 | 0.55 | 0.78 |
Volatility | 22.58 | 24.35 | 32.58 |
Ø price 5 days | Ø volume 5 days (pcs.) | 24.66 EUR (71,067) |
Ø price 30 days | Ø volume 30 days (pcs.) | 24.06 EUR (77,645) |
Ø price 100 days | Ø volume 100 days (pcs.) | 27.33 EUR (86,978) |
Ø price 250 days | Ø volume 250 days (pcs.) | 31.92 EUR (84,829) |
YTD High | date | 39.00 EUR (2024/01/04) |
YTD Low | date | 23.02 EUR (2024/07/01) |
52 Weeks High | date | 40.26 EUR (2023/08/04) |
52 Weeks Low | date | 23.02 EUR (2024/07/01) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Vienna Stock Exchange | 2024/07/16 | 15:30 | 23.96 EUR | 0.00 | 4 |
Tradegate | 2024/07/16 | 22:26 | 24.20 EUR | 0.02 | 8 |
Stuttgart | 2024/07/16 | 13:33 | 24.00 EUR | 0.00 | 4 |
Munich | 2024/07/16 | 08:29 | 24.28 EUR | 0.00 | 2 |
London Stock Exchange European Trade Reporting | 2024/07/16 | 17:30 | 24.12 EUR | 0.00 | 2 |
Hanover | 2024/07/16 | 08:21 | 23.96 EUR | 0.00 | 3 |
Frankfurt | 2024/07/16 | 21:50 | 23.96 EUR | 0.00 | 3 |
FINRA other OTC Issues | 2024/06/21 | 18:11 | 22.60 USD | 0.00 | 1 |
Euronext Milan MTF Trading After Hours | 2024/06/06 | 18:00 | 24.30 EUR | 0.00 | 1 |
Euronext Amsterdam | 2024/07/16 | 17:35 | 24.24 EUR | 1.11 | 656 |
Duesseldorf | 2024/07/16 | 08:10 | 24.02 EUR | 0.00 | 3 |
Berlin | 2024/07/16 | 21:50 | 24.18 EUR | 0.00 | 19 |
GALAPAGOS NV |
- - |
Industriepark Mechelen Noord, Generaal de Wittelaan L11 A3 - 2800 Mechelen |
Telefon: +32-1-534-29-00 |
Fax: + |
E-mail: - |
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium. |
Paul Stoffels | Chairman of Managing Board |
Annelies Missotten | Member of Executive Committee |
Thad Huston | Member of Executive Committee |
Valeria Cnossen | Member of Executive Committee |
Dan Baker | Member of Supervisory Board |
Lena Elisabeth Svanberg | Member of Supervisory Board |
Linda Higgins | Member of Supervisory Board |
Simon Sturge | Member of Supervisory Board |
Susanne Antonie Schaffert | Member of Supervisory Board |
Andrew Dickinson | Member of Supervisory Board |
Jérôme Contamine | Member of Supervisory Board |
Peter Guenter | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer